Imaging and Treating Cancer with Carbon Nanotube Technology

Zaibaq, Nicholas G.; Moghaddam, Sakineh E.; Wilson, Lon J.

doi:10.1007/978-3-319-89878-0_5

Cited by 1 publication

(1 citation statement)

References 212 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, nanoparticles such as silicon nanoparticles [1], superparamagnetic iron oxide nanoparticles [2], and carbon nanotubes [3][4][5] have been studied extensively for biomedical applications as they constitute a promising platform upon which therapeutic, imaging, and/or targeting agents can be loaded [6][7][8]. Specifically, C 60 fullerene shows promise for biomedical applications because this multi-functional platform also has a variety of inherent advantages [9].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the Biodistribution of Serinolamide-Derivatized C60 Fullerene

et al. 2020

Self Cite

View full text Add to dashboard Cite

Carbon nanoparticles have consistently been of great interest in medicine. However, there are currently no clinical materials based on carbon nanoparticles, due to inconsistent biodistribution and excretion data. In this work, we have synthesized a novel C60 derivative with a metal chelating agent (1,4,7-Triazacyclononane-1,4,7-triacetic acid; NOTA) covalently bound to the C60 cage and radiolabeled with copper-64 (t1/2 = 12.7 h). Biodistribution of the material was assessed in vivo using positron emission tomography (PET). Bingel-Hirsch chemistry was employed to functionalize the fullerene cage with highly water-soluble serinolamide groups allowing this new C60 conjugate to clear quickly from mice almost exclusively through the kidneys. Comparing the present results to the larger context of reports of biocompatible fullerene derivatives, this work offers an important evaluation of the in vivo biodistribution, using experimental evidence to establish functionalization guidelines for future C60-based biomedical platforms.

show abstract